Loading patent…
AssigneesPeptron, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsDong Seok Kim, Hee Kyung Kim, Nigel H. Greig
Estimating the term…
The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject. The method includes administering to the systemic blood circulation of the subject a therapeutically effective amount of a neuroprotective polypeptide by a controlled-release formulation or a device providing a sustained release of the neuroprotective polypeptide including at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analogue; the neuroprotective polypeptide binds to and activates a receptor that binds at least one of GLP-1, exendin-4, or a combination thereof; and the controlled-release neuroprotective formulation or the sustained release of the neuroprotective polypeptide enhances the delivery of the neuroprotective polypeptide across a blood-brain barrier (BBB) of the subject to at least a portion of the CNS relative to a rapid release formulation of the neuroprotective polypeptide. Also disclosed is a method of treating a subject with a CNS-related disease or reducing at least one symptom of a CNS-related disease in a subject in need thereof.
A method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject, the method comprising:
A method of treating a subject with a central nervous system (CNS)-related disease or reducing at least one symptom of a CNS-related disease in a subject in need thereof, the method comprising:
Dependencies are inferred from the claim text.